复宏汉霖(02696)：欧盟委员会(EC)批准斯鲁利单抗注射液两项新增适应症

智通财经05-10

智通财经APP讯，复宏汉霖(02696)发布公告，近日，欧盟委员会(European Commission，EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(斯鲁利单抗)两项新增适应症。本次获批适应症为：(1)斯鲁利单抗联合氟尿嘧啶类及铂类化疗适用于PD-L1综合阳性评分(CPS)≥5、不可切除的局部晚期、复发或转移性食管鳞状细胞癌(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2634423354?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-10 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634423354","market":"hk","top_or_hot":-1,"title":"复宏汉霖(02696)：欧盟委员会(EC)批准斯鲁利单抗注射液两项新增适应症","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，欧盟委员会(European Commission，EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(斯鲁利单抗)两项新增适应症。本次获批适应症为：(1)斯鲁利单抗联合氟尿嘧啶类及铂类化疗适用于PD-L1综合阳性评分(CPS)≥5、不可切除的局部晚期、复发或转移性食管鳞状细胞癌(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439905.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：欧盟委员会(EC)批准斯鲁利单抗注射液两项新增适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：欧盟委员会(EC)批准斯鲁利单抗注射液两项新增适应症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-10 18:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1439905.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，欧盟委员会(European Commission，EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(斯鲁利单抗)两项新增适应症。本次获批适应症为：(1)斯鲁利单抗联合氟尿嘧啶类及铂类化疗适用于PD-L1综合阳性评分(CPS)≥5、不可切除的局部晚期、复发或转移性食管鳞状细胞癌(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439905.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EC","symbol_name":"哥伦比亚国家石油","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1439905.html","article_id":"2634423354","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634423354","pubTimestamp":1778408419,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 发布公告，近日，欧盟委员会已批准本公司自主开发的斯鲁利单抗注射液两项新增适应症。此次获批意味着斯鲁利单抗两项新增适应症在所有欧盟成员国及冰岛、列支敦士登和挪威获得批准。此次EC批准主要是基于两项随机、双盲、多中心3期临床研究。此外，2026年3月，斯鲁利单抗获欧洲药品管理局人用药品委员会积极审评意见，推荐批准本次两项新增适应症。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"EC":"哥伦比亚国家石油","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02696":"复宏汉霖","BK4201":"综合性石油与天然气企业","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"Henlius (02696): The European Commission (EC) approves two new indications for Slulizumab injection","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EC":1.5,"02696":1.5},"content_text":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，欧盟委员会(European Commission，EC)已批准本公司自主开发的斯鲁利单抗注射液(中国境内商品名：汉斯状®;欧盟商品名：HETRONIFLY®)(斯鲁利单抗)两项新增适应症。本次获批适应症为：(1)斯鲁利单抗联合氟尿嘧啶类及铂类化疗适用于PD-L1综合阳性评分(CPS)≥5、不可切除的局部晚期、复发或转移性食管鳞状细胞癌(ESCC)成人患者的一线治疗，及(2)斯鲁利单抗联合卡铂与培美曲塞适用于EGFR基因突变阴性、ALK或ROS1阴性的不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌(nsNSCLC)成人患者的一线治疗(本次两项新增适应症)。此次获批意味着斯鲁利单抗两项新增适应症在所有欧盟成员国及冰岛、列支敦士登和挪威(各自为欧洲经济区(EEA)国家)获得批准。此次EC批准主要是基于两项随机、双盲、多中心3期临床研究。研究结果表明：(1)斯鲁利单抗联合化疗(顺铂和5- 氟尿嘧啶)对比化疗(顺铂和5- 氟尿嘧啶)治疗既往未接受过治疗的局部晚期或转移性食管鳞状细胞癌(ESCC) 获益显著，达到预设的主要终点标准，且具有良好的安全性和耐受性; (2)斯鲁利单抗联合化疗(卡铂-培美曲塞)对比化疗(卡铂-培美曲塞)治疗既往未接受过治疗的晚期非鳞状非小细胞肺癌(nsNSCLC)获益显著，达到预设的主要终点标准，且具有良好的安全性和耐受性。2023年12月，本集团收到荷兰卫生监督机构(Health and Youth Care Inspectorate)颁发的数项GMP证书，说明斯鲁利单抗相关生产线已符合欧盟GMP标准。此外，2026年3月，斯鲁利单抗获欧洲药品管理局(EMA)人用药品委员会(CHMP)积极审评意见，推荐批准本次两项新增适应症。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634423354","isCrawlerRequest":true}